Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 49

1.

Corticosteroid use and mortality risk in patients with perforated colonic diverticular disease: a population-based cohort study.

Broersen LHA, Horváth-Puhó E, Pereira AM, Erichsen R, Dekkers OM, Sørensen HT.

BMJ Open Gastroenterol. 2017 Apr 6;4(1):e000136. doi: 10.1136/bmjgast-2017-000136. eCollection 2017.

2.

Patient perceptions of glucocorticoid side effects: a cross-sectional survey of users in an online health community.

Costello R, Patel R, Humphreys J, McBeth J, Dixon WG.

BMJ Open. 2017 Apr 3;7(4):e014603. doi: 10.1136/bmjopen-2016-014603.

3.
4.

Dexamethasone does not diminish sugammadex reversal of neuromuscular block - clinical study in surgical patients undergoing general anesthesia.

Rezonja K, Mars T, Jerin A, Kozelj G, Pozar-Lukanovic N, Sostaric M.

BMC Anesthesiol. 2016 Oct 21;16(1):101.

5.

Glucocorticoid therapy and ocular hypertension.

Dibas A, Yorio T.

Eur J Pharmacol. 2016 Sep 15;787:57-71. doi: 10.1016/j.ejphar.2016.06.018. Epub 2016 Jul 5. Review.

PMID:
27388141
6.

Systemic glucocorticoid therapy and adrenal insufficiency in adults: A systematic review.

Joseph RM, Hunter AL, Ray DW, Dixon WG.

Semin Arthritis Rheum. 2016 Aug;46(1):133-41. doi: 10.1016/j.semarthrit.2016.03.001. Epub 2016 Mar 9.

7.

Increased glycogen synthase kinase-3β and hexose-6-phosphate dehydrogenase expression in adipose tissue may contribute to glucocorticoid-induced mouse visceral adiposity.

Yan C, Yang H, Wang Y, Dong Y, Yu F, Wu Y, Wang W, Adaku U, Lutfy K, Friedman TC, Tian S, Liu Y.

Int J Obes (Lond). 2016 Aug;40(8):1233-41. doi: 10.1038/ijo.2016.57. Epub 2016 Apr 22.

8.

Corticosteroids: Mechanisms of Action in Health and Disease.

Ramamoorthy S, Cidlowski JA.

Rheum Dis Clin North Am. 2016 Feb;42(1):15-31, vii. doi: 10.1016/j.rdc.2015.08.002. Review.

9.

[Prevalence of complications of corticosteroid therapy among West African consulting in rheumatology].

Zomalheto Z, Dossou-yovo H, Zossoungbo F, Avimadjè M.

Pan Afr Med J. 2015 Aug 26;21:304. doi: 10.11604/pamj.2015.21.304.5805. eCollection 2015. French. No abstract available.

10.

Glucocorticoid (dexamethasone)-induced metabolome changes in healthy males suggest prediction of response and side effects.

Bordag N, Klie S, Jürchott K, Vierheller J, Schiewe H, Albrecht V, Tonn JC, Schwartz C, Schichor C, Selbig J.

Sci Rep. 2015 Nov 3;5:15954. doi: 10.1038/srep15954.

11.

Specificity and sensitivity of glucocorticoid signaling in health and disease.

Cain DW, Cidlowski JA.

Best Pract Res Clin Endocrinol Metab. 2015 Aug;29(4):545-56. doi: 10.1016/j.beem.2015.04.007. Epub 2015 Apr 25. Review.

12.

Adrenal suppression in patients taking inhaled glucocorticoids is highly prevalent and management can be guided by morning cortisol.

Woods CP, Argese N, Chapman M, Boot C, Webster R, Dabhi V, Grossman AB, Toogood AA, Arlt W, Stewart PM, Crowley RK, Tomlinson JW.

Eur J Endocrinol. 2015 Nov;173(5):633-42. doi: 10.1530/EJE-15-0608. Epub 2015 Aug 20.

13.

The impact of persistence with bisphosphonates on health resource utilization and fracture risk in the UK: a study of patient records from the UK Clinical Practice Research Datalink.

Ferguson S, Feudjo Tepie M, Taylor A, Roddam A, Critchlow C, Iqbal M, Spangler L, Bayly J.

J Eval Clin Pract. 2016 Feb;22(1):31-39. doi: 10.1111/jep.12422. Epub 2015 Aug 16.

14.

Evaluating glucocorticoid administration on biomechanical properties of rats' tibial diaphysis.

Freidouni M, Nejati H, Salimi M, Bayat M, Amini A, Noruzian M, Asgharie MA, Rezaian M.

Iran Red Crescent Med J. 2015 Mar 31;17(3):e19389. doi: 10.5812/ircmj.19389. eCollection 2015 Mar.

15.

Monitoring of patients on long-term glucocorticoid therapy: a population-based cohort study.

Fardet L, Petersen I, Nazareth I.

Medicine (Baltimore). 2015 Apr;94(15):e647. doi: 10.1097/MD.0000000000000647.

16.

Fracture rate associated with quality metric-based anti-osteoporosis treatment in glucocorticoid-induced osteoporosis.

Overman RA, Gourlay ML, Deal CL, Farley JF, Brookhart MA, Layton JB.

Osteoporos Int. 2015 May;26(5):1515-24. doi: 10.1007/s00198-014-3022-9. Epub 2015 Jan 20.

17.

The hypertension of Cushing's syndrome: controversies in the pathophysiology and focus on cardiovascular complications.

Isidori AM, Graziadio C, Paragliola RM, Cozzolino A, Ambrogio AG, Colao A, Corsello SM, Pivonello R; ABC Study Group.

J Hypertens. 2015 Jan;33(1):44-60. doi: 10.1097/HJH.0000000000000415. Review.

18.

Possible role of lymphocytes in glucocorticoid-induced increase in trabecular bone mineral density.

Grahnemo L, Jochems C, Andersson A, Engdahl C, Ohlsson C, Islander U, Carlsten H.

J Endocrinol. 2015 Jan;224(1):97-108. doi: 10.1530/JOE-14-0508. Epub 2014 Oct 30.

19.

Medication-induced osteoporosis: screening and treatment strategies.

Panday K, Gona A, Humphrey MB.

Ther Adv Musculoskelet Dis. 2014 Oct;6(5):185-202. doi: 10.1177/1759720X14546350. Review.

20.

11β-HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess.

Morgan SA, McCabe EL, Gathercole LL, Hassan-Smith ZK, Larner DP, Bujalska IJ, Stewart PM, Tomlinson JW, Lavery GG.

Proc Natl Acad Sci U S A. 2014 Jun 17;111(24):E2482-91. doi: 10.1073/pnas.1323681111. Epub 2014 Jun 2.

Supplemental Content

Support Center